GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Evolent Health Inc (NYSE:EVH) » Definitions » Piotroski F-Score

Evolent Health (Evolent Health) Piotroski F-Score : 5 (As of May. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Evolent Health Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Evolent Health has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Evolent Health's Piotroski F-Score or its related term are showing as below:

EVH' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 7
Current: 5

During the past 11 years, the highest Piotroski F-Score of Evolent Health was 7. The lowest was 1. And the median was 4.


Evolent Health Piotroski F-Score Historical Data

The historical data trend for Evolent Health's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolent Health Piotroski F-Score Chart

Evolent Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 3.00 7.00 3.00 5.00

Evolent Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 3.00 5.00 5.00

Competitive Comparison of Evolent Health's Piotroski F-Score

For the Health Information Services subindustry, Evolent Health's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolent Health's Piotroski F-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Evolent Health's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -19.982 + -34.323 + -25.324 + -33.411 = $-113 Mil.
Cash Flow from Operations was -7.974 + 0.654 + 60.521 + 89.381 = $143 Mil.
Revenue was 427.69 + 469.136 + 511.015 + 556.055 = $1,964 Mil.
Gross Profit was 117.215 + 117.198 + 124.43 + 101.627 = $460 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(1817.293 + 2589.459 + 2646.831 + 2669.615 + 2680.308) / 5 = $2480.7012 Mil.
Total Assets at the begining of this year (Dec22) was $1,817 Mil.
Long-Term Debt & Capital Lease Obligation was $635 Mil.
Total Current Assets was $684 Mil.
Total Current Liabilities was $674 Mil.
Net Income was -5.35 + -4.588 + 2.123 + -11.349 = $-19 Mil.

Revenue was 297.057 + 319.939 + 352.585 + 382.432 = $1,352 Mil.
Gross Profit was 77.318 + 70.234 + 85.968 + 83.064 = $317 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1419.458 + 1339.149 + 1303.912 + 1759.182 + 1817.293) / 5 = $1527.7988 Mil.
Total Assets at the begining of last year (Dec21) was $1,419 Mil.
Long-Term Debt & Capital Lease Obligation was $469 Mil.
Total Current Assets was $478 Mil.
Total Current Liabilities was $433 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Evolent Health's current Net Income (TTM) was -113. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Evolent Health's current Cash Flow from Operations (TTM) was 143. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-113.04/1817.293
=-0.06220241

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-19.164/1419.458
=-0.01350093

Evolent Health's return on assets of this year was -0.06220241. Evolent Health's return on assets of last year was -0.01350093. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Evolent Health's current Net Income (TTM) was -113. Evolent Health's current Cash Flow from Operations (TTM) was 143. ==> 143 > -113 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=635.058/2480.7012
=0.25599939

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=468.996/1527.7988
=0.30697498

Evolent Health's gearing of this year was 0.25599939. Evolent Health's gearing of last year was 0.30697498. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=683.673/674.242
=1.01398756

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=478.054/433.442
=1.10292496

Evolent Health's current ratio of this year was 1.01398756. Evolent Health's current ratio of last year was 1.10292496. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Evolent Health's number of shares in issue this year was 113.612. Evolent Health's number of shares in issue last year was 99.867. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=460.47/1963.896
=0.23446761

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=316.584/1352.013
=0.23415751

Evolent Health's gross margin of this year was 0.23446761. Evolent Health's gross margin of last year was 0.23415751. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=1963.896/1817.293
=1.08067109

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=1352.013/1419.458
=0.95248539

Evolent Health's asset turnover of this year was 1.08067109. Evolent Health's asset turnover of last year was 0.95248539. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Evolent Health has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Evolent Health  (NYSE:EVH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Evolent Health Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Evolent Health's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolent Health (Evolent Health) Business Description

Traded in Other Exchanges
Address
800 N. Glebe Road, Suite 500, Arlington, VA, USA, 22203
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. The company's two reportable segments: EHS and Clinical Solutions. The Company's EHS segment provides an integrated administrative and clinical platform for health plan administration and value-based business infrastructure and clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for specialty care management in oncology and cardiology and increasingly the musculoskeletal markets and holistic total cost of care improvement. It generates a majority of its revenue from Clinical Solutions segment.
Executives
Seth Blackley officer: President 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Daniel Joseph Mccarthy officer: PRESIDENT 800 N GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Emily Ann Rafferty officer: Chief Operating Officer 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Toyin Ajayi director 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Mary Bridget Duffy director C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Diane Holder director 800 GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Richard M Jelinek director 40 W 47TH STREET, FLOOR 33, NEW YORK NY 10035
Frank J Williams director, officer: Chief Executive Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
John Paul Johnson officer: Chief Financial Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Jonathan Weinberg officer: General Counsel 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Steve Tutewohl officer: Chief Operating Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Tunde Sotunde director 800 N. GLEBE RD, SUITE 500, ARLINGTON VA 22203
Kim Keck director 30 W. MONROE STREET, SUITE 1200, CHICAGO IL 60603
Craig A. Barbarosh director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305